Rapport Therapeutics, Inc. (RAPP) ROE
- 2026-06-30: ROE -32.43%.
- 2026-03-31: ROE -22.75%.
- 2025-12-31: ROE -23.00%.
- 2025-09-30: ROE -19.10%.
Complete source-backed roe history.
- Available history
- 2023-12-31 to 2026-06-30
- Data captured
Historical ROE
| Date | ROE |
|---|---|
| 2026-06-30 | -32.43% |
| 2026-03-31 | -22.75% |
| 2025-12-31 | -23.00% |
| 2025-09-30 | -19.10% |
| 2025-06-30 | -33.51% |
| 2025-03-31 | -27.88% |
| 2024-12-31 | -25.64% |
| 2024-09-30 | -22.24% |
| 2024-06-30 | -18.71% |
| 2024-03-31 | 129.46% |
| 2023-12-31 | 135.70% |
Annual ROE
| Date | ROE |
|---|---|
| 2025-12-31 | -23.00% |
| 2024-12-31 | -25.64% |
| 2023-12-31 | 135.70% |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |